Scorpion Therapeutics is excited to announce a monumental funding round that has successfully raised $2.5 billion, a significant boost for the clinical-stage precision oncology company dedicated to transforming cancer treatment. This substantial investment will enable Scorpion to accelerate its innovative pipeline, which is already making waves with its lead program, STX-478, a mutant-selective PI3Ka inhibitor designed to target previously undruggable cancer variants. The funding will support the advancement of three internally discovered clinical product candidates and several discovery-stage programs that aim to fill critical gaps in therapeutic options for patients battling cancer. By leveraging its proprietary, fully-integrated discovery capabilities, Scorpion is pushing the boundaries of cancer biology, medicinal chemistry, and data sciences to deliver exquisitely selective therapies. The company is committed to improving patient outcomes, and this infusion of capital will both enhance its research capabilities and expand its clinical trials, ultimately bringing the promise of precision oncology closer to those who need it most. As Scorpion Therapeutics forges ahead in the fight against cancer, the focus remains on creating transformational treatments that not only address the challenges of current therapies but also provide hope for patients faced with limited options. With this funding, Scorpion is poised to make significant strides in the oncology landscape, reinforcing its commitment to pioneering innovative, targeted solutions that have the potential to redefine therapy for cancer patients worldwide.
Scorpion Therapeutics Secures $250 Million in Funding to Advance Precision Oncology Therapies
Recently funded 路 $2.5BPharmaceuticals
Get the full Scorpion Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
